A PET study evaluating dopamine D 2 receptor occupancy for long-acting injectable risperidone

American Journal of Psychiatry

Volumn 163, Issue 3, 2006, Pages 396-401

  Remington, Gary ^a   Mamo, David ^a   Labelle, Alain ^a   Reiss, Jeffrey ^a   Shammi, Chekkera ^a   Mannaert, Erik ^a   Mann, Steve ^a   Kapur, Shitij ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; LONG ACTING DRUG; PALIPERIDONE; PROLACTIN; RACLOPRIDE; RISPERIDONE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; CARBON; DIAGNOSTIC AGENT; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOPAMINE RELEASE; DOSE RESPONSE; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CORPUS STRIATUM; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; INJECTION; METABOLISM; MIDDLE AGED; PSYCHOSIS; SCHIZOPHRENIA; SCINTISCANNING;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRAIN; CARBON RADIOISOTOPES; CORPUS STRIATUM; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS; ISOXAZOLES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROLACTIN; PSYCHOTIC DISORDERS; PYRIMIDINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA;

EID: 33645913544     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.163.3.396     Document Type: Article

References (48)

1. Davis JM, Andriukaitis S: The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986; 6(suppl 1):2S-10S
2. Glazer WM, Kane JM: Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53:426-433
3. Citrome L, Levine J, Allingham B: Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 1996; 32:321-326
4. Dencker SJ: Depot neuroleptics: a Scandinavian view. Acta Psychiatr Belg 1981; 81:115-120
5. Johnson DA: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 1984; 45:13-21
6. Rothbard AB, Kuno E, Foley K: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29:531-540
7. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia, second edition. Am J Psychiatry 2004; 161(Feb suppl)
8. Emsley R, Oosthuizen P: Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2004; 7:219-238
9. Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:103-108; correction, 159:514
10. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54:719-723
11. Eerdekens M, Van Hove I, Remmerie B, Mannaert E: Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004; 70:91-100
12. Ramstack M, Grandolfi GP, Mannaert E, D'Hoore P, Lasser RA: Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb microsphere technology. Schizophr Res 2003; 60(suppl 1):314
13. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64:1250-1257
14. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160:1125-1132
15. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M: Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65:1084-1089
16. Taylor DM, Young CL, Mace S, Patel MX: Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004; 65:1076-1083
17. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520
18. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
19. Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989; 99(suppl):S28-S31
20. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
21. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
22. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161:818-825
23. 11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997; 17:437-447
24. 2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21:1034-1057
25. 11C]raclopride binding using a bolus plus infusion protocol, in Quantification of Brain Function Using PET. Edited by Myers R, Cunningham V, Bailey D, Jones T. London, Academic Press, 1996, pp 262-265
26. 2 receptors from plasma levels. Psychopharmacology (Berl) 2000; 149:1-5
27. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231:258-261
28. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001; 158:360-369
29. 2 occupancy: a positron emission tomographic study (letter). J Clin Psychopharmacol 1998; 18:82-83
30. Curry SH: The strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 1985; 5:263-271
31. McCreadie RG, Mackie M, Wiles DH, Jorgensen A, Hansen V, Menzies C: Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry 1984; 144:625-629
32. McIntyre IM, Gershon S: Interpatient variations in antipsychotic therapy. J Clin Psychiatry 1985; 46:3-5
33. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, Muller MJ: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26:156-160
34. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28(suppl 1):53-67
35. 2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998; 18:305-310
36. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S: Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002; 7:317-321
37. Belmaker RH, Bersudsky Y: Mechanism of atypicality of anti-psychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1067-1069
38. Blin O: A comparative review of new antipsychotics. Can J Psychiatry 1999; 44:235-244
39. Remington G: Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci 2003; 28:275-284
40. 123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000; 150:132-140
41. 123I] epidepride single photon emission tomography (SPET) study. Br J Psychiatry 1999; 175:231-238
42. 123I]-epidepride SPET study. J Clin Psychopharmacol 2003; 23:5-14
43. 123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160:1413-1420
44. Lidow MS, Williams GV, Goldman-Rakic PS: The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998; 19:136-140
45. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW: Limbic selectivity of clozapine (letter). Lancet 1997; 350:490-491
46. 2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21:207-214
47. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179:503-508
48. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, Remmerie B, Eerdekens M, Nyberg S: Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005; 8:27-36